Paper Details

  1. Home
  2. Paper Details

Long-acting muscarinic antagonists (LAMA) added to combination long-acting beta2-agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for adults with asthma.

Author: DahriKaren, KewKayleigh M

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

Combination medications for asthma, like long-acting beta2-agonists and inhaled corticosteroids (LABA/ICS), can help control symptoms and reduce flare-ups. However, some people don't achieve good control with these medications. A new type of inhaler, long-acting muscarinic antagonists (LAMA), used successfully for lung disease, is now being used for asthma alongside LABA/ICS.
Paper Details　
Original Abstract of the Article :
Maintenance treatment with long-acting beta2-agonists and inhaled corticosteroids (LABA/ICS) can relieve asthma symptoms and reduce the frequency of exacerbations, but there are limited treatment options for people who do not gain control on combination LABA/ICS. Long-acting muscarinic antagonists (...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9440477/

データ提供：米国国立医学図書館（NLM）

Long-Acting Muscarinic Antagonists (LAMAs): A New Oasis in the Desert of Asthma Management

Asthma, a chronic respiratory condition, can significantly impact an individual's quality of life. This study explores the potential of long-acting muscarinic antagonists (LAMAs), a class of inhaled medications, as an additional treatment option for patients with asthma who do not achieve adequate control with standard combination therapy of long-acting beta2-agonists and inhaled corticosteroids (LABA/ICS). The authors review the evidence for the efficacy of LAMAs in treating asthma, highlighting their potential to improve symptom control and reduce exacerbations.

The review suggests that LAMAs may be a valuable addition to standard asthma therapy, particularly for patients who remain symptomatic despite optimal LABA/ICS treatment. The authors discuss the mechanism of action of LAMAs, highlighting their ability to relax airway muscles and reduce airway inflammation.

Expanding the Oasis of Asthma Management

This review highlights the potential of LAMAs as a new and valuable tool in the management of asthma. The findings suggest that LAMAs may be particularly beneficial for patients who do not achieve adequate control with standard LABA/ICS therapy, offering a potential oasis in the desert of asthma management.

Navigating the Desert of Asthma Treatment

Just as a camel navigates a vast and unforgiving desert, individuals with asthma often face challenges in managing their condition. This review offers valuable insights into the potential of LAMAs as an additional treatment option, expanding the oasis of asthma management and providing new pathways to improved symptom control and quality of life.

Dr. Camel's Conclusion

This review highlights the potential of long-acting muscarinic antagonists (LAMAs) as a valuable addition to standard asthma therapy, offering a potential oasis in the desert of asthma management. Further research is needed to fully understand the efficacy and safety of LAMAs in treating asthma.

Date :
  1. Date Completed 2016-05-10
  2. Date Revised 2022-09-05
Further Info :

Pubmed ID

26798035

DOI: Digital Object Identifier

PMC9440477

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.